Pomalidomide-d4

CAT:
804-HY-10984S2
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Pomalidomide-d4 - image 1

Pomalidomide-d4

  • UNSPSC Description:

    Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<
  • Target Antigen:

    Apoptosis; Isotope-Labeled Compounds; Ligands for E3 Ligase; Molecular Glues
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Apoptosis;Others;PROTAC
  • Applications:

    Cancer-programmed cell death
  • Field of Research:

    Cancer
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=C1N(C2C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)C(C3=C(N)C=CC=C31)=O
  • Molecular Weight:

    277.27
  • References & Citations:

    [1]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7.;Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 a|[2]Hernandez-Ilizaliturri FJ, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92.|[3]Yuan Xiao Zhu, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7.;Hernandez-Ilizaliturri FJ1,
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1416575-78-4